QUESTIONS
PT-141 Questions, Answered Plainly
Direct, cited answers to the questions people actually ask about bremelanotide.
How big is the effect of bremelanotide on sexual desire?
Modest but real. In two Phase 3 trials of 1,267 premenopausal women with HSDD, bremelanotide 1.75 mg raised a standardized desire score by +0.35 and lowered desire-related distress by -0.33 versus placebo (both P<.001) over 24 weeks [3]. An effect-size analysis put drugs like it near 1.0, but placebo alone reached about 0.55, so the true drug-specific gap is smaller [10].
Does PT-141 cause weight loss?
Not at its approved use, but the receptor it targets is involved in appetite. In two Phase 1 studies, high-frequency research dosing (up to 2.5 mg, three times daily) in obese women reduced body weight (about -1.3 kg vs placebo over 16 days) and caloric intake by roughly 400 kcal/day, via MC4R [8]. That is far above the approved as-needed dose and is not an approved use [7].
Why is PT-141 being studied with a PDE-5 inhibitor?
Because the two work in completely different places. PT-141 acts centrally in the brain on melanocortin receptors to raise desire, while PDE-5 inhibitors act peripherally on blood-vessel muscle to improve blood flow [1]. Combining a brain-side and a blood-flow-side mechanism is a logical research idea, since they address different parts of the sexual-response chain rather than overlapping [1].
What is PT-141?
PT-141, drug name bremelanotide, is a synthetic cyclic peptide that activates melanocortin receptors (mainly MC4R) in the brain [1]. It is a redesigned copy of the natural messenger alpha-MSH [1]. It works on the central nervous system to influence sexual desire — not on blood flow — and is FDA-approved for low desire in premenopausal women [7].
What is PT-141 peptide?
The PT-141 peptide is a cyclic heptapeptide: seven amino acids joined in a ring, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, molecular weight about 1,025 daltons [7]. The ring (a lactam bridge) makes it sturdier than a straight-chain peptide [7]. It is a brain-acting melanocortin receptor agonist, also known by the drug name bremelanotide [1].
What does the PT-141 peptide do?
It activates melanocortin receptors (MC4R/MC3R) in the brain's desire circuits [1]. In animals it produced erections and lit up hypothalamic nerve cells; in trials it raised sexual desire and lowered desire-related distress in premenopausal women with HSDD [1][3]. It works centrally on motivation rather than peripherally on blood flow [1].
What is PT-141 used for?
Its one FDA-approved use is treating acquired, generalized HSDD — low sexual desire causing distress — in premenopausal women [7]. Every other use, including in men, postmenopausal women, or for performance or weight, is off-label or experimental and not approved [7]. This site documents the research; it gives no medical advice.
Is PT-141 the same as bremelanotide?
Yes. "PT-141" is the development code and "bremelanotide" is the international nonproprietary name (INN) for the same molecule [7]. One caution: the FDA-approved bremelanotide injection is a regulated drug, while "PT-141" sold as a research chemical sits outside that framework with no oversight of identity or purity [7].
What is bremelanotide?
Bremelanotide is the drug name for PT-141, a melanocortin (MC3R/MC4R) receptor agonist [1]. It is a synthetic cyclic peptide modeled on alpha-MSH that acts in the brain to influence sexual desire [1]. The FDA approved it in 2019 for HSDD in premenopausal women [7].
How does PT-141 work?
It activates melanocortin receptors — chiefly MC4R — in hypothalamic circuits that govern sexual motivation, and is thought to engage dopamine signaling tied to desire [1][2]. The key point is that it works centrally, in the brain, rather than peripherally on blood flow the way erection pills do [1].
What receptors does PT-141 act on?
Mainly the melanocortin 4 receptor (MC4R), with secondary action at the melanocortin 3 receptor (MC3R), both concentrated in the central nervous system [1]. It can also activate the peripheral MC1R, which is linked to the skin-darkening seen with frequent dosing [7].
Does PT-141 work through the brain or through blood flow?
Through the brain. PT-141 acts centrally on melanocortin receptors in the hypothalamus to influence desire and arousal at their source [1]. A 2022 brain-imaging study showed a single dose changed how women's brains processed erotic cues and raised desire for up to 24 hours [5]. It does not act on vascular smooth muscle like PDE-5 inhibitors [1].
What is a melanocortin receptor agonist?
A melanocortin receptor agonist is a substance that switches on the melanocortin receptors (a family of five docking sites, MC1R-MC5R) that normally respond to body signals like alpha-MSH [1]. PT-141 is one such agonist, acting mainly on the brain's MC4R and MC3R to influence sexual desire [1].
Does PT-141 increase testosterone?
No. PT-141 does not act through the hormone axis that controls testosterone and does not directly raise it — a common misconception [7]. It works on melanocortin receptors in the brain to influence desire, a completely separate pathway from sex-hormone production [1].
How is PT-141 different from PDE-5 inhibitors?
Location and mechanism. PDE-5 inhibitors act peripherally on blood-vessel muscle to improve erectile blood flow; PT-141 acts centrally in the brain on melanocortin receptors to influence desire and arousal [1]. One addresses blood flow, the other addresses motivation — which is why they are sometimes studied together [1].
What is the PT-141 dosage?
The FDA-approved dosage, for HSDD in premenopausal women, is 1.75 mg injected subcutaneously as needed — no more than once per 24 hours and no more than eight doses per month [7]. The drug has a terminal half-life of about 2.7 hours [7]. This is the labeled dose, not a recommendation for any individual.
How much PT-141 should I take?
This site gives no personal dosing advice. The label documents an approved dose of 1.75 mg subcutaneously as needed for the one approved use, with strict frequency limits [7]. Any decision about taking an approved prescription medicine belongs with a licensed clinician, not a website.
How much PT-141 to inject?
The approved bremelanotide injection is labeled at 1.75 mg subcutaneously, as needed, with a ceiling of one dose per 24 hours and eight per month [7]. We describe this as the documented label dose only and recommend no amount for any person; a licensed clinician handles individual dosing.
What is the PT-141 dosage for women?
For premenopausal women with HSDD, the approved dosage is 1.75 mg subcutaneously, as needed [7]. This is the only regulator-approved dosing. The female-specific rationale traces to animal work showing PT-141 selectively increased desire-driven sexual behavior in female rats [2].
How do you reconstitute PT-141?
The FDA-approved bremelanotide is supplied as a ready-to-use prefilled autoinjector, not a powder a person mixes [7]. Reconstitution questions usually refer to unregulated "research chemical" powder, which sits outside the pharmacy framework with no oversight of identity or purity — this site offers no preparation instructions [7].
How do you take PT-141?
The approved product is given as a subcutaneous (under-the-skin) injection, taken as needed at least 45 minutes before anticipated activity, within the once-daily and eight-per-month limits [7]. We describe the labeled administration only and give no personal instructions; a licensed clinician handles individual use.
How often can you take PT-141?
The approved label caps it at one dose per 24 hours and no more than eight doses per month [7]. That ceiling reflects the as-needed trial design and limits side effects linked to frequent dosing, such as skin darkening [7]. The 52-week extension study confirmed this pattern stayed safe over a year [4].